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SUMMARY
Graft-versus-host disease (GVHD) has been the primary limitation to the wider application of allogeneic bone
marrow transplantation (BMT). The pathophysiology of acute GVHD is complex and can be conceptualized to be
a three-step process based on murine studies. In step 1, the conditioning regimen leads to the damage and
activation of host tissues and induces the secretion of inflammatory cytokines. As a consequence, the expression of
MHC antigens and adhesion molecules is increased enhancing the recognition of host alloantigens by donor T
cells. Donor T-cell activation in step 2 is characterized by donor T cell interaction with host APCs and subsequent
proliferation, differentiation and secretion of cytokines. Cytokines such as IL-2 and IFN- enhance T-cell
expansion, induce cytotoxic T cells (CTL) and natural killer (NK) cell responses and prime additional mono-
nuclear phagocytes to produce TNF- and IL-1. These inflammatory cytokines in turn stimulate production of
inflammatory chemokines, thus recruiting effector cells into target organs. In step 3, effector functions of
mononuclear phagocytes are triggered via a secondary signal provided by lipopolysaccaride (LPS) that leaks
through the intestinal mucosa damaged during step 1. This mechanism may result in the amplification of local
tissue injury and further promotion of an inflammatory response, which, together with the CTL and NK
components, leads to target tissue destruction in the transplant host. The following review discusses the three-
step process of the pathophysiology of experimental acute GVHD. Copyright # 2003 John Wiley & Sons, Ltd.
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INTRODUCTION
The ability of allogeneic stem cell transplantation (SCT) to cure certain hematologic malignancies is
widely recognized. An important therapeutic aspect of SCT in eradicating malignant cells is the graft-
versus-leukemia (GVL) effect. Forty years ago Barnes and colleagues noted that recipients of
allogeneic grafts, although less likely to relapse, died of a ‘wasting syndrome’ now recognized as
graft-versus-host disease (GVHD).1,2 Thus, in addition to describing GVL, these experiments high-
lighted for the first time the intricate relationship between GVL and GVHD. Ten years after the work of
Barnes and Loutit, Billingham formulated the requirements for the development of GVHD: the graft
must contain immunologically competent cells, the recipient must express tissue antigens that are not
present in the transplant donor and the recipient must be incapable of mounting an effective response to
destroy the transplanted cells.3 Clinical GVHD occurs secondary to mismatches between histocom-
patibility antigens between the donor and recipient.4,5 Matching of the major histocompatibility
complex (MHC) antigens speeds engraftment and reduces the severity of GVHD.4 Despite HLA
identity between a patient and donor, substantial numbers of patients still develop GVHD due to
differences in minor histocompatibility antigens that lie outside the HLA loci. But the precise
elucidation of many human minor antigens is yet to be accomplished.6,7 Acute GVHD can occur
within days or as late as 2 months after transplantation. The incidence ranges from less than 10 to more
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than 80%, depending on the degree of histoincompatibility between donor and recipient, the number of
T cells in the graft, the patient’s age and the GVHD prophylactic regimen.8 The principal target organs
include the immune system, skin, liver and intestine. Pathologically, the sine qua non of acute GVHD
is selective epithelial damage of target organs.9,10 Standard grading systems generally include clinical
changes in the skin, GI tract, liver and performance status.11 While mild GVHD (grade I or II) is
associated with little morbidity and almost no mortality, higher grades are associated with significantly
decreased survival.11 With grade IV GVHD, the mortality is greater than 90%.
Since the early experiments by Brent and Billingham, both GVHD and the GVL effect have been
studied extensively, particularly in murine models of transplantation.12 This review summarizes the
current understanding of the pathophysiology of acute GVHD. Two important principles help to place
the pathophysiology of GVHD in context. The first is that GVHD is not a disease per se; it reflects
exaggerated but normal physiologic inflammatory mechanisms of the donor lymphocytes that have
been infused into the recipient, given the foreign environment they encounter. The second principle is
that donor lymphocytes are infused into a host that has been profoundly damaged by the underlying
disease, prior infections and the intensity of the conditioning regimen. Thus the allogeneic donor cells
rapidly encounter not only a foreign environment, but one that has been altered to promote the
activation and proliferation of inflammatory cells by the increased expression of adhesion molecules,
cytokines and co-stimulatory proteins. Thus the pathophysiology of acute GVHD is complex but can
be conceptualized in three sequential phases: (1) effects of conditioning (2) donor T cell activation
which constitutes the afferent phase and (3) efferent effector phase (Figure 1).13
This review will focus on the complex interactions of the donor T cells, NK cells, host antigen
presenting cells and the cytokines and chemokines as they relate to the three phases of the
pathophysiology of acute GVHD.
PHASE 1: EFFECTS OF CONDITIONING
The first step involves the conditioning regimen that may include total body irradiation (TBI) and/or
chemotherapy (Figure 1). Donor T cells are infused into a host that has been profoundly damaged by
underlying disease, infection and conditioning, all of which result in activation of host cells with
secretion of proinflammatory cytokines, such as TNF- and IL-1.14 The presence of inflammatory
cytokines during this phase increases the expression of adhesion molecules, co-stimulatory molecules
and MHC antigens.15,16 Such ‘danger signals’ expressed by injured host tissues are critical for the
activation of host dendritic cells (DCs) and are necessary for the initiation of the alloreaction.17 This
concept of altered host milieu promoting an alloreaction explains a number of clinical observations such
as increased risks of GVHD associated with advanced stage leukemia, certain intensive conditioning
regimens and histories of viral infections.18,19 TBI is particularly important because it also induces
endothelial apoptosis in the gastrointestinal tract followed by epithelial cell damage,20 allowing
immunostimulatory microbial products such as LPS to enter into systemic circulation, leading to
further amplification of GVHD.21 The relationship between conditioning intensity, inflammatory
cytokine and GVHD severity was further supported by animal models and clinical observation.22
PHASE 2: DONOR T CELL ACTIVATION, PROLIFERATION AND DIFFERENTIATION
GVHD fundamentally depends on donor T cell interaction with host antigen-presenting cells and their
subsequent activation, proliferation and differentiation. This process occurs during the second step of
the afferent phase of acute GVHD (Figure 1). The central role of host APC has recently been
established by elegant murine studies which demonstrated that host APCs alone are sufficient to
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activate donor T cells.23 Although alloantigen can be presented directly by host-derived and indirectly
by donor-derived APCs, host-derived APCs appear to be critical in inducing GVHD across both MiHA
and MHC mismatches.23,24 Furthermore a recent murine study identified the enhanced allostimulatory
activity of host APCs in aged mice as one of the important reasons for greater severity of GVHD in
aged recipients.25 APCs are activated by (1) inflammatory cytokines such as TNF- and IL-1, (2)
microbial products such as LPS and CpG entering systemic circulation from intestinal mucosa
Figure 1. Pathophysiology of GVHD. During step 1, irradiation and chemotherapy both damage and activate host
tissues, including intestinal mucosa, liver and the skin. Activated cell hosts then secrete inflammatory cytokines
(e.g. TNF- and IL-1), which can be measured in the systemic circulation. The cytokine release has important
effects on antigen presenting cells (APCs) of the host, including increased expression of adhesion molecules (e.g.
ICAM-1, VCAM-1) and of MHC class II antigens. These changes in the APCs enhance the recognition of host
MHC and/or minor H antigens by mature donor T cells. During step 2, donor T-cell activation is characterized by
proliferation of GVHD T cells and secretion of the Th1 cytokines IL-2 and IFN-. Both of these cytokines play
central roles in clonal T-cell expansion. Induction of CTL and NK cell responses and the priming of mononuclear
phagocytes: in step 3, mononuclear phagocytes primed by IFN- are triggered by a second signal such as
endotoxin (LPS) to secrete cytopathic amounts of IL-I and TNF-. LPS can leak through the intestinal mucosa
damaged by the conditioning regimen, to stimulate gut-associated lymphoid tissue or Kupffer cells in the liver;
LPS that penetrates the epidermis may stimulate keratinocytes, dermal fibroblasts and macrophages to produce
similar cytokines in the skin. This mechanism results in the amplification of local tissue injury and further
production of inflammatory effectors such as nitric oxide, which, together with CTL and NK effectors, leads to the
observed target tissue destruction in the stem cell transplant host. CTL effectors use Fas/FasL, perforin/granzyme
B and membrane-bound cytokines to lyse target cells
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damaged by conditioning and (3) necrotic cells that are damaged by recipient conditioning.17,26 These
effects are extremely important in producing the ‘danger signals’ that enhance the maturity of APCs
and induce T cell activation.17 But the relative in vivo contribution of the professinal APCs such as the
dendritic cells and other semiprofessional APCs such as monocytes/macrophages and B cells in the
induction of GVHD is yet to be determined. Donor T cells require the second signal from the co-
stimulatory molecules provided by the APC.27,28 Interruption of the second signal by blockade of the
co-stimulatory molecules has been shown to reduce GVHD in some murine models.29 Furthermore
changes in phase 1 dramatically augment the signals delivered through CD28 that lower the threshold
for T-cell activation and promote T-cell differentiation and survival.30
Proliferation and apoptosis
Donor T cells proliferate following activation. The alloantigen composition of the host determines which
T-cell subset proliferates and differentiates. In mouse models of GVHD, where genetic differences
between multiple strain combinations can be controlled, CD4þ cells induce GVHD to MHC class II
differences and CD8þ cells induce GVHD to MHC class I differences.31 In the majority of HLA-
identical HSC transplants, GVHD may be induced by either subset or by both subsets in response to
MiHA, which are derived from the expression of polymorphic genes that distinguish host from donor.30
Following proliferation some of the alloreactive donor T cells are eliminated by the process of deletion
as an apparent mechanism to regulate the severity of the immune response. Deletional mechanisms of
tolerance can be placed into two categories: (1) central (thymic) deletion and (2) peripheral deletion.32
Central clonal deletion might be an effective way to deal with continued thymic production of
alloreactive T cells. To this end, lymphoablative treatments have been used as a condition to create a
mixed hematopoietic chimeric state in murine BMT models.33,34 In this instance, donor cells seed the
thymus and maturing donor-reactive T cell clones are deleted through intrathymic apoptosis.33,34
However, a definitive role for central deletion in attenuating GVHD in humans is yet to be demonstrated.
The proportion of the peripheral T cell repertoire that can respond to allogeneic MHC can play a
critical role in the development of tolerance.35 In the case of MHC-mismatched transplantation, the
frequency of alloreactive T cells is at least five orders of magnitude greater than the frequency of
peptide-specific T cells responding to a nominal antigen.35,36 The pathways of T-cell apoptosis by
which peripheral deletion occurs can be broadly categorized into activation-induced cell death (AICD)
and passive cell death (PCD).35 Probably the most important mediator of AICD in T cells is the Fas
receptor.37 Activated T cells induced to express the Fas molecule can undergo apoptotic cell death
when brought into contact with cells expressing Fas ligand. A critical role for Fas-mediated AICD has
been clearly demonstrated in attenuation of acute GVHD by the Th1 cytokines.38–41
PCD (or death by neglect), illustrates the exquisite dependence of activated T cells on growth factors
(e.g. IL-2, IL-4, IL-7, and/or IL-15) for survival; apoptotic cell death in this instance is largely due to
rapid downregulation of Bcl-2. Transplantation of Bcl-xL T cells into non-irradiated recipients
significantly exacerbated GVHD, however no difference in GVHD mortality was observed in animals
that had been lethally irradiated.42
Selective elimination of donor T cells in vivo after BMT using transgenic T cells in which a
thymidine kinase (TK) suicide gene is targeted to the T cell, has also been shown to attenuate the
severity of acute GVHD.43 More recently selective depletion of alloantigen-specific donor T cells by a
photodynamic cell-purging process (wherein donor T cells are treated with photoactive 4,5-dibro-
morhodamine 123 and subsequently exposed to visible light) has been shown to prevent GVHD.44
Thus several deletional mechanisms which are not necessarily mutually exclusive have been shown
to reduce the severity of acute GVHD. However the conditions under which one or the other of these
deletional mechanisms plays a critical role, remain to be determined.
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T-cell differentiation and cytokine secretion
The T-cell activation and proliferation is followed by their differentiation characterized by secretion of
cytokines and chemokines.45 Alloantigen presentation induces the activation of individual T cells
resulting in activation of several, rapidly occurring intracellular biochemical changes that activate
transcription of genes for cytokines and their receptors.45,46 The Th1 cytokines are preferentially
produced and have been implicated in the pathophysiology of acute GVHD.22,47 Th1 cells producing
IL-2 have a pivotal role in controlling and amplifying the immune response against alloantigens,
representing step 2 of the cytokine cascade which initiates acute GVHD.47,48 Experimental data show
that IL-2 is secreted primarily by donor CD4þ T cells and addition of low doses of IL-2 after
allogeneic BMT enhanced the severity and mortality of GVHD.49,50 The precursor frequency of host-
specific IL-2-producing cells (pHTL) predicts the occurrence of GVHD after transplantation between
HLA-identical siblings.51 Due to their apparent importance in initiating acute GVHD, IL-2-producing
donor T cells have been the target of many experimental approaches to control GVHD. Cyclosporine
(CSP) and FK506, inhibitors of IL-2 production, are effective prophylactic agents against GVHD.47
The importance of IL-2 is further underscored by experiments showing that monoclonal antibodies
(mAbs) against the IL-2 receptor are efficient in preventing GVHD in animal models.52 However,
treatment with anti-IL-2 receptor mAb was only moderately successful in reducing the incidence of
severe GVHD in clinical studies.53,54 Interestingly a recent study of the kinetics of T-cell division and
expression of IL-2 and IL-15 receptor subunits, demonstrated that IL-15 is a critical cytokine in
initiating allogeneic T-cell division in vivo.55 Elevated serum levels of IL-15 are associated with acute
GVHD in humans.56 IL-15 may therefore be a critical factor in initiating GVHD. IFN- is another
crucial cytokine that can be implicated in the second step of the pathophysiology of acute GVHD.21
IFN- levels are significantly higher in mice with GVHD than those without it.57 The release of IFN-
is also an early event in the cascade leading to GVHD because IFN- production in animals with
GVHD peaks at day 7 post-transplant before clinical manifestations are apparent.13 In several models
of experimental acute GVHD, T cells produce large amounts of IFN- and a large proportion of T-cell
clones isolated from GVHD patients also produce IFN-.21,58,59 Experimental data suggest that IFN-
is involved in several aspects of acute GVHD pathophysiology. First, IFN- upregulates numerous
molecules such as adhesion molecules, chemokines, MHC and its associated machinery molecules,
which are important for antigen presentation. Thus IFN- facilitates antigen presentation and effector
recruitment.47 Second, IFN- can mediate the development of pathologic processes in the gastro-
intestinal tract and skin during GVHD.60,61 Third, IFN- mediates GVHD-associated immuno-
suppression in several experimental GVHD systems through the induction of nitric oxide (NO) and
Fas.62–64 Fourth, exposure to IFN- results in a significant reduction in the amount of LPS needed to
trigger macrophages to produce proinflammatory cytokines and NO.65 Lastly, IFN- also plays an
important role in regulating the death of activated donor T cells by enhancing Fas-mediated apoptosis,
thus regulating GVHD.40,66
Th1/Th2 paradigm
Differential activation of Th1 or Th2 cells has been evoked in the pathogenesis of GVHD.67 The role of
Th1/Th2 polarization as it relates to acute GVHD is incompletely understood and controversial.
Although the ‘cytokine storm’ amplified by the Th1 phenotype correlates with the development of
acute GVHD,68,69 early Th1 polarization of donor T cells by administration of cytokines such as IFN-
, IL-2, IL-12 and IL-18 to BMT recipients can attenuate acute GVHD.40,70–72 Furthermore the use of
Th1 cytokine-deficient mice as BMT donors still results in GVHD;73–75 and some studies failed to
show a beneficial effect of Th2 polarization on acute GVHD.73,76–78 Thus, a physiological and
adequate amount of Th1 cytokine production is critical for GVHD induction, while inadequate
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production (extremely low or high) could modulate GVHD through a breakdown of negative feedback
mechanisms for activated donor T cells. However Th2 polarization of donor T cells by IL-4, both
in vivo and ex vivo,69 the use of G-CSF and IL-18 to mobilize donor cells,69,79 administration of
IL-1180 and the secretion of IL-4 by NK1.1þT cells,81 all reduce acute GVHD. However the causal
mechanisms of these effects are yet to be completely determined. One study suggested that Th1 and
Th2 subsets cause injury of distinct target tissues;82 Th2 (Stat 4/) cells were required for hepatic
damage and Th1 cells (Stat6/) for GI tract damage after allogeneic BMT. Taken together, these
data demonstrate that the timing of administration or the production of any given cytokine, the
intensity of the conditioning regimen and the donor–recipient strain combination may be critical to
the eventual outcome of acute GVHD.
Regulatory T cells
Several recent studies have demonstrated a critical role for donor CD4 (þ) CD25 (þ) regulatory T (T
(reg)) cells in the regulation of acute GVHD. The balance of donor-type CD4 (þ) CD25 (þ) T (reg)
and conventional CD4 (þ) CD25 () T cells can determine the outcome of acute GVHD.83 The ability
of CD4þ CD25þ regulatory T cells to suppress GVH reactivity after BMT depended partially on IL-
10 production and or CD28 expression, the mechanisms for in vivo generation of these cells are not
known.83,84 Ex vivo-expanded CD4 (þ) CD25 (þ) regulatory T cells obtained after stimulation by
allogeneic recipient-type antigen-presenting cells can also modulate GVHD.85 Furthermore ex vivo
blockade of the CD40: CD40L or LIGHT: CD40L co-stimulatory pathway in primary mixed
lymphocyte reaction cultures generated regulatory T cells that protected from GVHD.86–89
Chemokines and T cell migration
Chemokines play a critical role in the migration of immune cells to secondary lymphoid organs and
target tissues. Recruitment of CCR5þ T cells that usually secrete Th1 cytokines are associated with
the development of hepatic GVHD.90 T-lymphocyte production of macrophage inflammatory protein-
1alpha is critical to the recruitment of CD8 (þ) T but not CD4þ cells to the liver, lung and spleen
during acute GVHD.91,92 Several chemokines are over-expressed in GVHD target organs, such as
MIP-1alpha, MIP-2 and MIG in liver and spleen. MIP-1alpha, MIP-2, MCP-1 and MCP-3 are
predominantly expressed in other target organs such as the skin.93 Recently Choi et al. used mouse
models of GVHD to multiple minor H antigens in order to track donor T cells through several GVHD
target organs (spleen, liver, lung) in real-time and demonstrated that the donor T cells expanded
simultaneously in the liver, lung and spleen, suggesting that donor T cells interact directly with
antigen-presenting cells of the host not only in secondary lymphoid tissue but also in target organs.94
Resident APCs in target tissues may play an important role in the selectivity of target organ damage.95
Another recent study suggested that chemokine receptor CCR5 and integrin alpha(4)beta(7)-MAd-
CAM-1 (mucosal vascular addressin) interactions are critical for donor T-cell migration to APCs in
Peyer’s patches and the initiation of acute GVHD.96 However the role of various chemokines in
regulating donor T-cell migration to secondary lymphoid organs and/or GVHD target tissues remains
unexplored.
PHASE 3: CELLULAR AND INFLAMMATORY EFFECTOR PHASE
The efferent phase of acute GVHD is a complex cascade of multiple effectors mediated by (a) cellular
effectors such as CTLs and NK cells and (b) inflammatory effectors such as TNF-, IL-1 and NO
(Figure 1).13
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Cellular effectors
The cellular effectors of acute GVHD are primarily CTLs and NK cells.13 The Fas/Fas ligand (FasL)
and the perforin/granzyme (or granule exocytosis) pathways are the classic effector mechanisms that
CTLs and NK cells utilize to lyse target cells.97,98
Cytotoxic T lymphocytes
Transplantation of perforin-deficient T cells resulted in a marked delay in the onset of GVHD in
transplants across MiHA disparities, but mortality and histological signs of GVHD were induced in the
absence of perforin-dependent killing.99 The importance of the perforin/granzyme pathway for GVHD
induction has been evident in studies employing donor T-cell subsets. Perforin or granzyme B-deficient
CD8þ T cells induced significantly less mortality compared to wild type T cells in experimental
transplants across a single MHC class I mismatch, while this pathway seems to be less important
compared to the Fas/FasL pathway in CD4-mediated GVHD.100,101 Thus, it has been thought that
CD4þ CTLs preferentially use the Fas/FasL pathway, while CD8þ CTLs mostly use the perforin/
granzyme pathways. Most studies failed to detect a role for the perforin/granzyme pathway in target
organ pathology.102
In contrast, FasL-mediated cytotoxicity may be a particularly important effector pathway in target
organ GVHD. FasL-defective T cells markedly diminish GVHD in liver, skin and lymphoid
organs.102 During GVHD, Fas expression on bile duct epithelial cells is upregulated103 and
administration of anti-FasL significantly blocked the hepatic damage occurring in murine models
of GVHD.104 Elevated serum levels of soluble FasL and Fas have been observed in at least some
patients with acute GVHD.105
The utilization of mutant mice provides the opportunity to address whether other effector
pathways are capable of inducing GVHD target organ pathology. An initial study demonstrated
that perforin/granzyme and FasL cytotoxic double deficient (cdd) T cells were unable to induce
GVHD lethality in recipients after sublethal irradiation.106 However, two subsequent studies
demonstrated that cytotoxic effector mechanisms of donor T cells are critical in preventing host
resistance to GVHD107,108 and with lethal irradiation, cdd T cells produced similar mortality to wild
type T cells in a murine model of GVHD.108 These results demonstrate that other effector molecules
are sufficient to induce GVHD mediated by T cells in the absence of perforin/granzyme and FasL-
dependent functions.
A recent study demonstrated that the absence of TRAIL on donor cells significantly reduced GVL
but resulted in similar severity of acute GVHD suggesting that donor T cells might utilize different
effector mechanisms in mediating GVH and GVL responses.109
NK cells
Recent studies have generated a tremendous amount of interest in the role of NK cells in GVHD.110
NK cells are negatively regulated by MHC class I-specific inhibitory receptors, thus HLA-mismatched
transplants may trigger donor NK-mediated alloreactivity.111 In murine models of BMT, infusion of
donor NK cells can reduce GVHD, probably through the elimination of host APCs112 or through the
secretion of TGF-.113 Interestingly, HLA class I disparity driving donor NK-mediated alloreactions
in the GVH directions, mediate strong GVL effects and produce higher engraftment rates without
causing acute GVHD.110 A recent murine BMT study using mice lacking SH2-containing inositol
phosphatase (SHIP), in which the NK compartment is dominated by cells that express two inhibitory
receptors capable of binding either self or allogeneic MHC ligands, suggests that host NK cells may
play a role in the initiation of GVHD.114
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Inflammatory effectors
The inflammatory cytokines TNF- and IL-1 are produced by monocytes and macrophages after
stimulation. This stimulus may be provided through Toll-like receptors (TLRs) by microbial products
such as LPS and other components of microbials which can leak through the intestinal mucosa or skin
damaged by the conditioning regimen and GVHD.21,115 Several experimental models strongly support
the role of mononuclear phagocytes as sources of inflammatory cytokines during the effector phase of
acute GVHD.13,116 Murine studies demonstrate that TNF- production by donor cells in response to
LPS predicts the severity of GVHD and that direct antagonism of LPS reduces GVHD.117 Thus, the
gastrointestinal tract plays a major role in the amplification of systemic GVHD and is critical in the
propagation of the ‘cytokine storm’ characteristics of acute GVHD.13
TNF- plays a critical role in the pathophysiology of intestinal GVHD in murine and human
studies104,118 and is also an important effector molecule in skin and lymphoid tissue.104,119
Furthermore target organ damage could be inhibited by infusion of anti-TNF- mAbs.120 A role
for TNF- in clinical acute GVHD has been suggested by studies demonstrating elevated levels of
TNF- in the serum of patients with acute GVHD. Regardless of the source, donor or the host, TNF-
plays an important role in acute GVHD.65,121 TNF- may be involved in a multi-step process of
GVHD pathophysiology. First, TNF- activates APCs and enhances alloantigen presentation.
Second, TNF- recruits effector T cells and monocytes into target organs via the induction of
inflammatory chemokines. Third, TNF- causes direct tissue damage by inducing apoptosis and
necrosis.13,21,122
The second major proinflammatory cytokine that appears to play an important role in the effector
phase of acute GVHD is IL-1.13 Secretion of IL-1 appears to occur predominantly during the effector
phase of GVHD of the spleen and skin, two major GVHD target organs.123 Mice receiving IL-1 after
allogeneic BMT displayed a wasting syndrome and increased mortality that appeared to be an
accelerated form of disease.124 Although administration of an IL-1 receptor antagonist (IL-1ra) to
recipients reduces GVHD mortality in animal models,125,126 a recent randomized human study failed
to demonstrate any benefit against acute GVHD.127 These data would suggest that IL-1 might have a
redundant and pleiotropic role in the disease and may be synergistic with TNF-.
Nitric oxide (NO) is another inflammatory effector molecule that plays an important role in GVHD.
Development of GVHD is preceded by an increase in serum levels of oxidation products.128,129 NO
also contributes to the deleterious effects on GVHD target tissues, particularly immunosuppres-
sion.130,131 As a result of activation during GVHD, macrophages produce NO and induce the release of
iron from target cells, resulting in an inhibition of the recovery of injured target tissues by inhibiting
proliferation of epithelial stem cells in the gut and skin.132
More recently a central role of inflammatory cytokines in acute GVHD was confirmed in a murine
study by using bone marrow chimeras wherein mortality and target organ injury was prevented by the
neutralization of TNF- and IL-1 particularly for CD4-mediated acute GVHD but also in part, for
CD8-mediated disease.23 These inflammatory effectors may synergize with the lytic component
provided by CTLs in a complex milieu of chemotactic signals and cytokine cascades resulting in the
amplification of local tissue injury and further promotion of an inflammatory response, which
ultimately leads to the observed target tissue destruction in the transplant recipient.
In conclusion the pathogenesis of acute GVHD involves a number of complex interactions between
several cell types of both donor and host. Although the disease process can be schematized in three
overall steps it should be noted that each of the three steps does not carry equal weight in its
pathogenesis. The pivotal interaction occurs in step 2, where host APCs activate allogeneic donor T
cells and the dysregulation of complex cytokine cascades occurs at various steps in the sequence and is
eventually responsible for the manifestations of this disease.
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Although some of these observations need to be validated in human studies further investigation into
the mechanisms of these cascades should provide insight into the unique target organ distribution of
acute GVHD as well as provide new strategies to prevent and treat this complicated disorder. Such
approaches might make allogeneic BMT safer and ultimately more available to many patients who
could benefit from this potent therapy.
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